Hemat El-Sayed El-Horany, Marwa Mohamed Atef, Muhammad Tarek Abdel Ghafar, Mohamed H Fouda, Nahla Anas Nasef, Islam Ibrahim Hegab, Duaa S Helal, Walaa Elseady, Yasser Mostafa Hafez, Rasha Youssef Hagag, Monira Abdelmoaty Seleem, Mai Mahmoud Saleh, Doaa A Radwan, Amal Ezzat Abd El-Lateef, Rania Nagi Abd-Ellatif
Pulmonary fibrosis (PF) is a life-threatening disorder that severely disrupts normal lung architecture and function, resulting in severe respiratory failure and death. It has no definite treatment. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has protective potential in PF. However, the mechanisms underlying these effects require further elucidation. Therefore, this study aimed to evaluate the ameliorative effect of EMPA against bleomycin (BLM)-induced PF and the potential mechanisms...
May 30, 2023: International Journal of Molecular Sciences